September 28, 2017 08:31 AM EDT
Deals

Buy­out buzz: No­var­tis has been kick­ing the tires at AAA as FDA re­views Lu­tathera — re­port

John Carroll

Editor & Founder

Af­ter work­ing through some sna­fus on its ap­pli­ca­tions for its ex­per­i­men­tal can­cer drug Lu­tathera, Bloomberg is re­port­ing that No­var­tis has been kick­ing the tires …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

A service from the Financial Times